The FDA decision on oral IDHIFA, proposed for the treatment of patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 (IDH2) mutation, is expected to be announced on August 30, 2017.IDHIFA, known generically as Enasidenib, is being jointly developed by Agios Pharmaceuticals Inc. (AGIO) in collaboration with Celgene Corp. (CELG).The NDA for IDHIFA was submitted based on results from a single arm phase I/II study in patients with advanced hematologic malignancies with an IDH2 mutation. The objective response rate (ORR) with IDHIFA was 41% and the complete response (CR) rate was 17% in patients with relapsed or refractory IDH2-mutant AML. The median duration of response was 6.9 months.According to updated phase I/II study results of IDHIFA reported in June of this year, the overall response rate 37 percent; complete response rate was 20.1 percent and median duration of response was 5.6 months.AGIO closed Friday's (July 28) trading at $56.57, up 0.60%.